Short Summary
Sanofi India Limited filed a suit against Ridley Life Science Private Limited alleging continuous violation of an earlier injunction order, specifically regarding the sale of products under the marks 'CONCIFLAM' and 'CORIFLAM'. The Plaintiff claimed that these infringing products were being sold despite the May 2021 restraint on using marks similar to its registered trademark 'COMBIFLAM'. The court noted the defendant's history of alleged habitual infringement in pharmaceutical preparations. Consequently, the court directed the defendant to submit detailed sales figures and imposed a significant deposit amount due to the persistent violations.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Sanofi India Limited vs Ridley Life Science Private Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Pioneer Bakeries (P) Ltd.vsNew Hope Food Industries Pvt. Ltd.
The Madras High Court disposed of multiple Original Petitions filed by Pioneer Bakeries (P) Ltd seeking cancellation of several trademarks. The court noted that both parties had reached a comprehensive Settlement Agreement dated March 26, 2018. This agreement defined specific usage rights for the 'MILKA' mark in Class 30, ensuring mutual non-infringement across various product categories. Consequently, the petitions were disposed of based on this existing compromise, avoiding a full judicial hearing.
M/s Munjal Showa LimitedvsM/s Star India Private Limited
The Madras High Court addressed a batch of petitions concerning the rectification and removal of several trademarks, including 'MANJAL.' The court accepted the first respondent's affidavit stating that some trademarks had expired and others were not being put to use despite renewal. Consequently, the court allowed the petitions, directing the first respondent to initiate necessary cancellation applications before the Trade Marks Registry within a specified timeframe.
Astrazeneca AbvsEmcure Pharmaceuticals Limited
The plaintiffs, AstraZeneca, allege that the defendants are infringing their patents related to the compound 'Dapagliflozin', used for treating type-2 diabetes. The plaintiffs seek an injunction against the defendants for not seeking licenses for the patents.
Sun Pharma Laboratories LtdvsB.B. Mohan Kumar Trading As East West Pharma & The Registrar of Trademarks
The Madras High Court dismissed the rectification petition filed by Sun Pharma Laboratories Ltd against Trademark No. 1764708. The court noted that the trademark in question had expired on December 17, 2018, and was not subsequently renewed. Consequently, the petitioner's request to remove the entry from the register became infructuous.
M/s.Microsoft Technology Licensing, LLC.vsAssistant Controller of Patents and Designs
Microsoft Technology Licensing appealed the refusal by the Assistant Controller of Patents and Designs to grant a patent for its computer-related invention, 'Delegating Instant Messaging Sessions'. The core dispute centered on whether the software met the criteria for patentability under Section 3(k) of the Patents Act. The Madras High Court ruled in favor of Microsoft, emphasizing that an invention based on a computer program is not automatically excluded if it demonstrates a clear technical effect or contribution, aligning with international jurisprudence and revised Patent Office guidelines.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.